Stock Scorecard

Stock Summary for Sage Therapeutics Inc (SAGE) - $8.28 as of 3/28/2025 8:55:59 PM EST

Total Score

13 out of 30

Safety Score

31 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for SAGE

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for SAGE

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for SAGE

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for SAGE

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for SAGE (31 out of 100)

Stock Price Rating (Max of 10) 4
Historical Stock Price Rating (Max of 10) 8
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 4
Book Value to Price (Max of 10) 2
Analyst Buy Ratings (Max of 5) 0
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 8
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for SAGE

Clearside Biomedical, Inc. ( CLSD ) Reports Q4 Loss, Tops Revenue Estimates 3/27/2025 9:20:00 PM
US Stocks Likely To Open Mixed: 'Expect Volatility. Buckle Up,' Says Expert 3/27/2025 9:56:00 AM
KB Home Posts Downbeat Results, Joins UniFirst, Oklo And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - KB Home ( NYSE:KBH ) , China Yuchai Intl ( NYSE:CYD ) 3/25/2025 12:38:00 PM
Notice to Long-Term Shareholders of Fluence Energy, Inc. ( NASDAQ: FLNC ) ; Kyverna Therapuetics, Inc. ( NASDAQ: KYTX ) ; Mercury Systems, Inc. ( NASDAQ: MRCY ) ; and Sage Therapeutics, Inc. ( NASDAQ: SAGE ) : Grabar Law Office Is Investigating Claims on Your Behalf - Kyverna Therapeutics ( NASDAQ:KYTX ) , Fluence Energy ( NASDAQ:FLNC ) 3/17/2025 7:01:00 PM
Notice to Long-Term Shareholders of Mercury Systems, Inc. ( NASDAQ: MRCY ) ; Methode Electronics, Inc. ( NYSE: MEI ) ; Monolithic Power Systems, Inc. ( NASDAQ: MPWR ) ; and Sage Therapeutics, Inc. ( NASDAQ: SAGE ) : Grabar Law Office Investigates Claims on Your Behalf - Methode Electronics ( NYSE:MEI ) , Monolithic Power Systems ( NASDAQ:MPWR ) 3/14/2025 5:29:00 PM
Can BIIB's New Drugs Revive Growth as Multiple Sclerosis Sales Fall? 3/14/2025 1:40:00 PM
Long-Term Shareholder Notice: Fluence Energy, Inc. ( NASDAQ: FLNC ) ; Kyverna Therapuetics, Inc. ( NASDAQ: KYTX ) ; Mercury Systems, Inc. ( NASDAQ: MRCY ) ; and Sage Therapeutics, Inc. ( NASDAQ: SAGE ) : Grabar Law Office Investigates Claims on Your Behalf - Kyverna Therapeutics ( NASDAQ:KYTX ) , Fluence Energy ( NASDAQ:FLNC ) 3/13/2025 10:21:00 PM
Sage Therapeutics ( SAGE ) Up 7.4% Since Last Earnings Report: Can It Continue? 3/13/2025 3:30:00 PM
Long-Term Shareholder Notice: Driven Brands Holdings, Inc. ( NASDAQ: DRVN ) ; Mercury Systems, Inc. ( NASDAQ: MRCY ) ; Playstudios, Inc. ( NASDAQ: MYPS ) ; and Sage Therapeutics, Inc. ( NASDAQ: SAGE ) : Grabar Law Office Investigates Claims on Your Behalf - Driven Brands Hldgs ( NASDAQ:DRVN ) , Mercury Sys ( NASDAQ:MRCY ) 3/12/2025 12:26:00 PM
Attention Long-Term Shareholders of Driven Brands Holdings, Inc. ( NASDAQ: DRVN ) ; Mercury Systems, Inc. ( NASDAQ: MRCY ) ; Playstudios, Inc. ( NASDAQ: MYPS ) ; and Sage Therapeutics, Inc. ( NASDAQ: SAGE ) : Grabar Law Office Investigates Claims on Your Behalf as Certain Class Actions Move Forward - Driven Brands Hldgs ( NASDAQ:DRVN ) , Mercury Sys ( NASDAQ:MRCY ) 3/10/2025 12:05:00 PM

Financial Details for SAGE

Company Overview
Ticker SAGE
Company Name Sage Therapeutics Inc
Country USA
Description Sage Therapeutics, Inc., a biopharmaceutical company, develops and markets drugs to treat disorders of the central nervous system. The company is headquartered in Cambridge, Massachusetts.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 12/31/2024
Next Earnings Date 4/23/2025

Stock Price History
Last Day Price 8.28
Price 4 Years Ago 42.54
Last Day Price Updated 3/28/2025 8:55:59 PM EST
Last Day Volume 855,240
Average Daily Volume 1,345,284
52-Week High 18.76
52-Week Low 4.62
Last Price to 52 Week Low 79.22%

Valuation Measures
Trailing PE N/A
Industry PE 37.01
Sector PE 40.10
5-Year Average PE -1.05
Free Cash Flow Ratio 0.55
Industry Free Cash Flow Ratio 11.91
Sector Free Cash Flow Ratio 47.05
Current Ratio Most Recent Quarter 7.42
Total Cash Per Share 15.09
Book Value Per Share Most Recent Quarter 7.58
Price to Book Ratio 1.14
Industry Price to Book Ratio 8.86
Sector Price to Book Ratio 21.92
Price to Sales Ratio Twelve Trailing Months 12.82
Industry Price to Sales Ratio Twelve Trailing Months 88.85
Sector Price to Sales Ratio Twelve Trailing Months 27.78
Analyst Buy Ratings 0
Analyst Strong Buy Ratings 3

Share Statistics
Total Shares Outstanding 61,481,000
Market Capitalization 509,062,680
Institutional Ownership N/A

Dividends
Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 26.01%
Reported EPS 12 Trailing Months -6.59
Reported EPS Past Year -6.23
Reported EPS Prior Year -10.31
Net Income Twelve Trailing Months -400,666,000
Net Income Past Year -400,666,000
Net Income Prior Year -541,489,000
Quarterly Revenue Growth YOY -83.60%
5-Year Revenue Growth 43.12%
Operating Margin Twelve Trailing Months -627.00%

Balance Sheet
Total Cash Most Recent Quarter 927,815,000
Total Cash Past Year 927,815,000
Total Cash Prior Year 1,435,376,000
Net Cash Position Most Recent Quarter 927,815,000
Net Cash Position Past Year 927,815,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 465,089,000
Total Stockholder Equity Prior Year 799,530,000
Total Stockholder Equity Most Recent Quarter 465,089,000

Free Cash Flow
Free Cash Flow Twelve Trailing Months -267,194,000
Free Cash Flow Per Share Twelve Trailing Months -4.35
Free Cash Flow Past Year -267,194,000
Free Cash Flow Prior Year -541,138,000

Options
Put/Call Ratio 0.03
Has Options Options Chain
Liquidity Rating

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD 0.21
MACD Signal 0.16
20-Day Bollinger Lower Band 4.59
20-Day Bollinger Middle Band 6.48
20-Day Bollinger Upper Band 8.37
Beta 0.82
RSI 63.87
50-Day SMA 8.81
150-Day SMA 25.66
200-Day SMA 30.33

System
Modified 3/28/2025 6:33:29 AM EST